Clinical Trial

HVA vs IA/DA or VA in the Treatment of ND HR-AML

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 6, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to evaluate the safety and efficacy of homohartonine combined with venetoclax and azacitidine (HVA) versus intensive chemotherapy (IA/DA) or venetoclax combined with azacitidine (VA) in newly diagnosed high-risk AML patients.
Trial Details
NCT Number NCT06810791
Lead Sponsor Nanfang Hospital, Southern Medical University
Collaborators: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou First People's Hospital, Guangdong Second Provincial General Hospital, Jiangmen Central Hospital, Shenzhen Second People's Hospital, First Affiliated Hospital of Guangxi Medical University, Dongguan People's Hospital, First People's Hospital of Foshan, Guangdong Provincial Hospital of Traditional Chinese Medicine, Huizhou Municipal Central Hospital, Shenzhen Hospital of Southern Medical University, Affiliated Hospital of Guangdong Medical University, People's Hospital of Guangxi Zhuang Autonomous Region, First People's Hospital of Chenzhou, Hunan Provincial People's Hospital, Ganzhou City People's Hospital, First Affiliated Hospital of Gannan Medical University
Conditions Newly Diagnosed Acute Myeloid Leukemia With High Risk
Enrollment 876 participants
Start Date 2025-01-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-06